These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 38162670)

  • 1. Bioavailable central nervous system disease-modifying therapies for multiple sclerosis.
    Hartung HP; Cree BAC; Barnett M; Meuth SG; Bar-Or A; Steinman L
    Front Immunol; 2023; 14():1290666. PubMed ID: 38162670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative safety of high-efficacy disease-modifying therapies in relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis.
    Śladowska K; Kawalec P; Holko P; Osiecka O
    Neurol Sci; 2022 Sep; 43(9):5479-5500. PubMed ID: 35713731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drugs for multiple sclerosis.
    Med Lett Drugs Ther; 2021 Mar; 63(1620):42-48. PubMed ID: 33976089
    [No Abstract]   [Full Text] [Related]  

  • 4. Ozanimod (Zeposia) for multiple sclerosis.
    Med Lett Drugs Ther; 2020 Aug; 62(1605):132-134. PubMed ID: 32970043
    [No Abstract]   [Full Text] [Related]  

  • 5. Safety and Monitoring of the Treatment with Disease-Modifying Therapies (DMTs) for Multiple Sclerosis (MS).
    Stamatellos VP; Papazisis G
    Curr Rev Clin Exp Pharmacol; 2023; 18(1):39-50. PubMed ID: 35418296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cladribine (Mavenclad) for multiple sclerosis.
    Med Lett Drugs Ther; 2019 Jul; 61(1577):118-120. PubMed ID: 31381552
    [No Abstract]   [Full Text] [Related]  

  • 7. Advances in oral immunomodulating therapies in relapsing multiple sclerosis.
    Derfuss T; Mehling M; Papadopoulou A; Bar-Or A; Cohen JA; Kappos L
    Lancet Neurol; 2020 Apr; 19(4):336-347. PubMed ID: 32059809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular and neuroimmune pharmacology of S1P receptor modulators and other disease-modifying therapies for multiple sclerosis.
    Kihara Y; Chun J
    Pharmacol Ther; 2023 Jun; 246():108432. PubMed ID: 37149155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative efficacy and acceptability of disease-modifying therapies in patients with relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis.
    Li H; Hu F; Zhang Y; Li K
    J Neurol; 2020 Dec; 267(12):3489-3498. PubMed ID: 31129710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Benefit-risk Assessment of Cladribine Using Multi-criteria Decision Analysis (MCDA) for Patients With Relapsing-remitting Multiple Sclerosis.
    Vermersch P; Martinelli V; Pfleger C; Rieckmann P; Alonso-Magdalena L; Galazka A; Dangond F; Phillips L
    Clin Ther; 2019 Feb; 41(2):249-260.e18. PubMed ID: 30846120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Siponimod (Mayzent)--a new drug for multiple sclerosis.
    Med Lett Drugs Ther; 2019 May; 61(1571):70-72. PubMed ID: 31169805
    [No Abstract]   [Full Text] [Related]  

  • 12. Efficacy and Safety of Oral Therapies for Relapsing-Remitting Multiple Sclerosis.
    Paolicelli D; Manni A; Iaffaldano A; Trojano M
    CNS Drugs; 2020 Jan; 34(1):65-92. PubMed ID: 31898276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sphingosine 1-Phosphate Receptor Modulators for Multiple Sclerosis.
    Roy R; Alotaibi AA; Freedman MS
    CNS Drugs; 2021 Apr; 35(4):385-402. PubMed ID: 33797705
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis.
    Zhu C; Zhou Z; Roos I; Merlo D; Kalincik T; Ozakbas S; Skibina O; Kuhle J; Hodgkinson S; Boz C; Alroughani R; Lechner-Scott J; Barnett M; Izquierdo G; Prat A; Horakova D; Kubala Havrdova E; Macdonell R; Patti F; Khoury SJ; Slee M; Karabudak R; Onofrj M; Van Pesch V; Prevost J; Monif M; Jokubaitis V; van der Walt A; Butzkueven H;
    J Neurol Neurosurg Psychiatry; 2022 Dec; 93(12):1330-1337. PubMed ID: 36261289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ponesimod (Ponvory) for multiple sclerosis.
    Med Lett Drugs Ther; 2021 Aug; 63(1630):123-125. PubMed ID: 34550110
    [No Abstract]   [Full Text] [Related]  

  • 16. Efficacy classification of modern therapies in multiple sclerosis.
    Samjoo IA; Worthington E; Drudge C; Zhao M; Cameron C; Häring DA; Stoneman D; Klotz L; Adlard N
    J Comp Eff Res; 2021 Apr; 10(6):495-507. PubMed ID: 33620251
    [No Abstract]   [Full Text] [Related]  

  • 17. Persistence, Adherence, and Switching to Higher-Cost Therapy in Patients with Multiple Sclerosis Initiating Oral Disease-Modifying Therapies: A Retrospective Real-World Study.
    Araujo L; Geertsen SS; Amedume A; Higuchi K; van Wingerden J
    Neurol Ther; 2022 Dec; 11(4):1735-1748. PubMed ID: 36152222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How to choose initial treatment in multiple sclerosis patients: a case-based approach.
    Apóstolos SLP; Boaventura M; Mendes NT; Teixeira LS; Campana IG
    Arq Neuropsiquiatr; 2022 May; 80(5 Suppl 1):159-172. PubMed ID: 35976318
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.